Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.52 |
| ▸ | CHRNG | P07510 | 1/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.52 |
| ▸ | CHRND | Q07001 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711945 | 1.00 | SLC15A2 (0.62) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL30900769 | 0.95 | SLC15A2 (0.58) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL29574640 | 0.94 | SLC15A2 (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL31556273 | 0.93 | GNPAT (0.60) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL31181203 | 0.92 | GNPAT (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL29904367 | 0.91 | OPRK1 (0.56) | SLC15A2GNPATGHSR | |
| SCHEMBL9318080 | 0.90 | SLC15A2 (0.60) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL9318061 | 0.90 | SLC15A2 (0.60) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL7122844 | 0.89 | SLC15A2 (0.59) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL30744249 | 0.89 | GNPAT (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536278-A2 | BIFUNCTIONAL CHELATORS AND CONJUGATES | Actinium Pharmaceuticals, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-11975081-B2 | Bifunctional chelators and conjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11964948-B2 | Bifunctional chelators and conjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240051928-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2023240135-A2 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| EP-2344478-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2011-07-20 | — | — | EP | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | SLC15A2 719/4885GNPAT 1927/4885ITGB3 4759/4885 |
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | SLC15A2 187/4885GNPAT 943/4885ITGB3 2604/4885 |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | SLC15A2 1084/4885GNPAT 1411/4885ITGB3 1894/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | SLC15A2 3444/4885GNPAT 2453/4885ITGB3 526/4885 |
| US-11964948-B2 | Bifunctional chelators and conjugates | FOLH1, PAICS, TAP2 | SLC15A2 187/4885GNPAT 943/4885ITGB3 2604/4885 |
| US-20240051928-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | SLC15A2 187/4885GNPAT 943/4885ITGB3 2604/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | SLC15A2 1251/4885GNPAT 1554/4885ITGB3 4742/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | SLC15A2 1177/4885GNPAT 1698/4885ITGB3 4750/4885 |
| US-11975081-B2 | Bifunctional chelators and conjugates | FOLH1, PAICS, TAP2 | SLC15A2 187/4885GNPAT 943/4885ITGB3 2604/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | SLC15A2 1332/4885GNPAT 1256/4885ITGB3 4747/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | SLC15A2 1084/4885GNPAT 1411/4885ITGB3 1894/4885 |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | SLC15A2 187/4885GNPAT 943/4885ITGB3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.